New Drug Ampydin – Info

    • Anonymous
      February 20, 2007 at 11:46 am

      [B]Orphan Drug 4-Aminopyridine (Ampydin) for Chronic Motor and Sensory Deficits of GBS[/B]

      On December 20, the FDA granted orphan drug status for an immediate release, orally administered version of 4-aminopyridine (Ampydin, made by Neurorecovery, Inc) in the treatment of chronic functional motor and sensory deficits resulting from Guillain-Barré syndrome (GBS).

      According to a company news release, 4-aminopyridine is currently on the FDA’s compounding for compassionate use list for treatment of certain neuropathies and for spinal cord injury and multiple sclerosis.

      An international phase 3 trial of the product for the GBS indication is expected to begin in the United States, Canada, and the European Union during the first half of 2007.

      Related Article =>

      Any additional information on exactly what this drug is and how it works would be great!


    • Anonymous
      February 26, 2007 at 1:11 pm

      This is the web address link to the company trying to get this drug approved. No new info availabe on this drug yet, but they do have “Newswire” and “Clinical Trials” links where you could check back for updated info.